Form 4: RA Capital Management Acquires Over 1.2 Million Shares of Tyra Biosciences

RA Capital Management, along with related entities and individuals, has acquired over 1.2 million shares of Tyra Biosciences at a price of $16.25 per share.

Summary

• RA Capital Management, L.P. and related entities have reported the acquisition of 1,220,681 shares of Tyra Biosciences common stock.
• The shares were purchased at a price of $16.25 per share on November 8, 2024.
• Following the transaction, RA Capital Management and related entities beneficially own a total of 8,697,956 shares directly through the RA Capital Healthcare Fund, L.P., 1,496,613 shares through the RA Capital Nexus Fund, L.P., and 442,721 shares through a separately managed account.
• The reporting individuals, Peter Kolchinsky and Rajeev Shah, disclaim beneficial ownership except to the extent of their pecuniary interest.
• Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.

Sentiment

Score: 7

Explanation: The document reflects a positive investment action by a major shareholder, which is generally viewed favorably. However, it is a routine filing and does not contain any extraordinary information.

Positives

• The purchase indicates a significant investment by RA Capital Management in Tyra Biosciences.
• The acquisition increases RA Capital Management's stake in the company, potentially signaling confidence in its future prospects.

Risks

• The document does not explicitly state any risks, but the concentration of ownership by RA Capital Management could pose a risk if their investment strategy changes.

Management Comments

• Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership of the reported securities, except to the extent of their pecuniary interest.
• Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.

Industry Context

This filing is a standard SEC Form 4, which is used to report changes in beneficial ownership of a company's securities. It is common for investment firms like RA Capital Management to file these forms when they make significant transactions in a company's stock.

Comparison to Industry Standards

• The transaction is typical for a large investment firm like RA Capital Management, which frequently adjusts its holdings in various companies.
• The filing is consistent with SEC regulations for reporting changes in beneficial ownership, similar to filings made by other investment firms.

Stakeholder Impact

• The increased stake by RA Capital Management could be viewed positively by shareholders, potentially increasing confidence in the company.
• The transaction does not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

RA Capital Management, Tyra Biosciences, Share Acquisition, Beneficial Ownership, SEC Form 4, Investment